Safe Harbor

Forward looking statements

This communication contains certain forward-looking statements, relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of Heidelberg Pharma AG. This material may not be distributed within countries where it may violate applicable law.
Heidelberg Pharma at a Glance

Developing new options to address major challenges in cancer therapy

Our Company

- Listed as Heidelberg Pharma AG
- Frankfurt Stock Exchange: WL6
- Shares outstanding: 28.21 million
- Market cap: ~€170 million (18 Mar 2020, €6.10)
- Headquarters: Ladenburg, Germany
- ~ 75 employees

Our Mission

- Inhibition of RNA Polymerase II – new option in cancer therapy
- Overcome resistance mechanisms
- Kill dormant tumor cells
- High efficacy on aggressive TP53/17p deleted tumors
- ATAC Technology

Our Approach

Unique mode of action
- Induction of apoptosis by inhibition of RNA Polymerase II
- Application of innovative payload by harnessing ADC therapeutic modality

Antibody Targeted Amanitin Conjugates (ATACs)
Strategic Cornerstones

- Build proprietary ATAC pipeline
- Sign technology licensing collaborations
- Additional upside potential with partnered non-ATAC legacy clinical assets

Proprietary lead candidate HDP-101
Other proprietary ATAC candidates GMP supply payload

Lead ATAC HDP-101
ATAC technology partnering
ATAC pipeline GMP supply
Partnered clinical assets

ATAC technology partnering with pharma and biotech
TLX250-CDx – imaging agent (REDECTANE®)
MESUPRON® - uPA inhibitor
Link Health, RedHill Biopharma

© Heidelberg Pharma AG
Achievements – Last 12 Months

Proprietary lead candidate HDP-101
• Core GMP manufacturing milestones achieved
• Preclinical GLP tox studies – first part completed
• HDP-101 clinical trial preparation
  ✓ Agreement signed with clinical CRO
  ✓ Clinical centers identified (US, GER)
  ✓ Synopsis issued
  ✓ CTA documentation begun

ATAC technology partnering
• Magenta Therapeutics
  ✓ 2nd licensing option exercised
  ✓ Development candidate MGTA-117 nominated
  ✓ CD45-ADC / CD117-ADC data presented at @ASH 2019 and TCT
• Emergence Therapeutics
  • Franco-German Joint Venture
  • Potential upside for minimal cost

ATAC platform & pipeline
• Compelling preclinical data on PSMA-ATAC and hematological follow-up candidates
• Biomarker 17p deletion validated with MD Anderson, US patent granted
• GMP manufacturing established for different Amanitin-linker derivatives
• EU Magic Bullet project extended by peptide-Amanitin conjugates

Partnered clinical assets
• TLX250-CDx (Telix)
  • New production process for Ab, milestone payment for HDP
  • Phase III trial recruiting in US, EU and Australia
• MESUPRON®
  • Link Health received IND to conduct clinical trials in China
## ATACs – Growing Pipeline of Proprietary and Partnered Programs

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Indication</th>
<th>Research</th>
<th>Preclinic</th>
<th>Clinic</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proprietary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDP-101</td>
<td>BCMA</td>
<td>Multiple myeloma (DLBCL/CLL)</td>
<td>I</td>
<td>II</td>
<td>III</td>
<td>Proprietary</td>
</tr>
<tr>
<td>PSMA-ATAC</td>
<td>PSMA</td>
<td>Prostate cancer</td>
<td>I</td>
<td>II</td>
<td></td>
<td>Proprietary</td>
</tr>
<tr>
<td>CDXX-ATAC</td>
<td>CDXX</td>
<td>NHL</td>
<td>I</td>
<td>II</td>
<td></td>
<td>Proprietary</td>
</tr>
<tr>
<td>CDXX-ATACs</td>
<td>CDXX</td>
<td>Solid / Hematological tumors</td>
<td>I</td>
<td>II</td>
<td></td>
<td>Proprietary, Open for partnering</td>
</tr>
<tr>
<td>ATAC technology partner</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGTA-XX-ATACs</td>
<td>CD117, CD45</td>
<td>HSCs, Conditioning programs for blood cancers and genetic diseases</td>
<td></td>
<td></td>
<td></td>
<td>Magenta</td>
</tr>
<tr>
<td>TAK-XX-ATACs</td>
<td>n/a</td>
<td>n/a</td>
<td>I</td>
<td>II</td>
<td></td>
<td>Takeda/Millennium</td>
</tr>
<tr>
<td>EMR-XX-ATAC</td>
<td>n/a</td>
<td>n/a</td>
<td>I</td>
<td>II</td>
<td></td>
<td>JV Emergence</td>
</tr>
</tbody>
</table>
Lead Proprietary ATAC Candidate HDP-101 – Status Update in Multiple Myeloma

- Amanitin + Linker + BCMA antibody = HDP-101
- Lead indication to validate approach – Multiple myeloma
  - BCMA is a validated target but need for better treatments for this incurable disease remain
- Additional indications: Diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL)
- Where do we stand?
  - Clinical trial start has been delayed due to manufacturing
  - Complete tox testing in 2020 to enable submission of CTA to start first-in-humans trial thereafter
  - Necessary components being put in place now so trial can start as soon as possible once CTA/IND approved
Solid Progress in Establishing Manufacturing Processes to Produce GMP Material

The world's first and so far only industrial source of chemically produced Amanitin
17p Deletion – Potential Biomarker for ATACs across Various Indications

- TP53 gene on chromosome 17 is frequently mutated (> 50%) in human cancer cells
- POLR2A gene frequently co-deleted with TP53
  → higher sensitivity to treatment with ATACs

University of Texas MD Anderson Cancer Center and Heidelberg Pharma AG findings:
- 10 x increased susceptibility to Amanitin in the case of loss of POLR2A in colorectal cancer
- HDP-101 active against myeloma with preferential efficacy against pre-clinical models of deletion 17p
- POLR2A potential biomarker to increase therapeutic window

**US patent rights granted for diagnosis and treatment of patients with TP53/RNA polymerase II deletion**

Biomarker offers potential to expedite clinical development
17p Deletion – Use of Biomarker Could Provide Opportunity for Accelerated Clinical Development

**Case study: HDP-101 for multiple myeloma**

- MM patients with 17p deleted tumors have a very high medical need for new treatment options.
- HDP-101 has preferential activity on 17p deleted tumor cells derived from MM patients.
- Potential options to speed-up market approval for such a selected patient population if preclinical data translate into clinical benefits.
- Potentially broader therapeutic window resulting in lower development risk and new treatment option for patient segment with bad prognosis.

**FDA programs to support innovative therapies**

- Fast Track
- Breakthrough Therapy
- Accelerated Approval
- Priority Review

Company to apply for Fast Track designation for HDP-101 at time of IND submission

Source: FDA
Collaboration enables and accelerates Magenta’s research and development efforts across several targeted conditioning programs for stem cell transplant with ATACs.
Partner Magenta: Making Important Progress in ATAC Programs for Conditioning

**CD117**
- Option exercised in October 2018
- Magenta product candidate: MGTA-117
- Compelling pre-clinical data presented at ASH Annual Meeting (Dec 2019) and Transplant and Cellular Therapy (TCT) Annual Meeting (Feb 2020)
  - Therapeutic index of MGTA-117 significantly higher than for other ADCs at this stage of development.
- Status:
  - Manufacturing scale-up ongoing
  - Plan to complete IND-enabling studies in 2020
  - Initial clinical data expected in 2021

**CD45**
- Option exercised in November 2019
- First data presented in Nov 2019 on use of targeted ADCs to reset immune system and halt progression of autoimmune disease
- Status:
  - GMP manufacturing started
  - Lead antibody identified and entered into IND-enabling studies
  - Plan to further advance candidate in 2020
Partner Telix: Advancing into Late-Stage Clinical Development

**TLX250-CDx® (formerly REDECTANE®) – diagnostic imaging agent**

- TLX250-CDx ($^{89}$Zr-DFO-Girentuximab) is a radiolabeled form of the antibody Girentuximab, which binds to the tumor-specific antigen CAIX on clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer
- Set-up of new and modernized production process for the antibody Girentuximab triggered milestone payment of USD 250k to Heidelberg Pharma
- August 2019: Start of PhIII Study (ZIRCON) for diagnosing renal cancer using positron emission tomography (PET):
  - Global multicenter pivotal trial in Australia, Europe & US with 250 patients undergoing kidney surgery

**TLX250 – therapeutic radioimmunoconjugate**

- Lutetium-177-labeled antibody Girentuximab (177Lu-TLX250) to be evaluated for disease-stabilizing effects in patients with advanced metastatic renal cancer
- INDs in the US for two trials in combination with immunotherapy planned for H1 2020

© Heidelberg Pharma AG
## Financial Review 2019

<table>
<thead>
<tr>
<th></th>
<th>Guidance 03/2019</th>
<th>Revised Guidance 10/2019</th>
<th>Actual 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue and other income</td>
<td>5.0 to 7.0</td>
<td>7.5 to 8.5</td>
<td>8.0</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>14.0 to 18.0</td>
<td>15.5 to 17.5</td>
<td>18.1</td>
</tr>
<tr>
<td>Operating result (EBIT)</td>
<td>(8.0) to (12.0)</td>
<td>(7.5) to (9.5)</td>
<td>(10.1)</td>
</tr>
<tr>
<td>Funds required</td>
<td>10.0 to 14.0</td>
<td>8.0 to 10.0</td>
<td>9.6</td>
</tr>
<tr>
<td>Funds required per month</td>
<td>0.9 to 1.2</td>
<td>0.7 to 0.9</td>
<td>0.8</td>
</tr>
</tbody>
</table>

- Sales guidance raised due to additional income from research collaborations, milestone payments and supply of Amanitin GMP material
- Operating expenses are slightly higher due to provisions for ongoing R&D expenses

### Financing

- Mixed non-cash and cash capital increase in November 2017: €34.4 m total transaction volume
- Cash at the end of 2019 financial year: €9.9 m + additional commitment of €15 m by main investor
- Cash reach is secured until mid 2021 based on current budget planning including additional commitment
• Sales revenue nearly doubled due to ATAC research collaborations, milestones and income from supply model
• Other income, including government grants, on a level with the previous year
• Cost of sales increased mainly due to supply of Amanitin linkers to licensing partners;
• R&D costs remained stable despite the expansion of cost-intensive external GMP production
• Administrative costs higher due to SOP as well as legal and operating consulting costs
• Net loss for the period reduced
Balance Sheet and Cash Flow 2019

- Average cash usage per month €0.8 m (2018: €0.9 m)
- Cash balance at Nov. 30, 2019: €9.9 m (2018: €19.4 m)
- Equity year-end 2019 decreased to €16.3 m (2018: €25.9 m)
- Equity ratio was 70.9% (2018: 83.0%)

<table>
<thead>
<tr>
<th>Assets (€ m)</th>
<th>30.11.2019</th>
<th>30.11.2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-current assets</td>
<td>11.4</td>
<td>10.9</td>
</tr>
<tr>
<td>Other current assets</td>
<td>1.7</td>
<td>0.9</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>9.9</td>
<td>19.4</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>23.0</strong></td>
<td><strong>31.2</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Equity and liabilities (€ m)</th>
<th>30.11.2019</th>
<th>30.11.2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current liabilities</td>
<td>6.5</td>
<td>5.3</td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td>0.2</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>Equity</strong></td>
<td><strong>16.3</strong></td>
<td><strong>25.9</strong></td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>23.0</strong></td>
<td><strong>31.2</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cashflow (€ m)</th>
<th>30.11.2019</th>
<th>30.11.2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating cash flow</td>
<td>-8.6</td>
<td>-10.0</td>
</tr>
<tr>
<td>Investing cash flow</td>
<td>-1.0</td>
<td>-1.0</td>
</tr>
<tr>
<td>Financing cash flow</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Exchange rate effects</td>
<td>-0.02</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>Net cash change</strong></td>
<td><strong>-9.6</strong></td>
<td><strong>-10.9</strong></td>
</tr>
</tbody>
</table>

- Average cash usage per month €0.8 m (2018: €0.9 m)
- Cash reach until mid 2021 including financing commitment of up to €15 m
Heidelberg Pharma Shares

Share performance 2019

- High: €3.390 (17 April 2019)
- Low: €1.980 (31 October 2019)
- Daily trading volume: 9,441 shares (FY 2018: 22,582)
- Shares outstanding: 28,209,611 (as of 29 February 2020)
- Market cap: ~€170 m (19 March 2020, €6.10)

Analyst coverage

- Pareto 03/20: target €4.20
- EQUI.TS 01/20: target €4.50
- MainFirst (Stifel) 11/19: target €4.10
Next Steps and Potential Milestones

ATAC technology and proprietary pipeline

HDP-101
- Complete GLP toxicity study
- Complete GMP manufacturing of clinical trial material
- Submit Clinical Trial Application in Germany/IND in US
- Prepare clinical development
- Continue biomarker development

Select next proprietary development candidate

Magenta collaboration
- Start MGTA-117 development program

Sign additional license and collaboration agreements

Partnered legacy clinical programs

TLX250-CDx®— imaging agent
- Telix: ZIRCON Phase III trial: patient recruitment in US, EU and Australia, completion planned by mid-2020
- Phase I/II (ZIRDAC-JP) study to be conducted in Japan

TLX250 - 177Lu-girentuximab
- Telix: Initiate trials with therapeutic radio-immuno-conjugate & checkpoint inhibitor in the US

MESUPRON® (upamostat)
- RedHill: Start Phase I/IIa three-arm trial with ABC294640 in combination with hydroxychloroquine and upamostat (RHB-107) in cholangiocarcinoma and exploratory program intended for the treatment of COVID-19
- Link Health: Revise development plan for China based on new NMPA regulations
## Financial Guidance 2020

<table>
<thead>
<tr>
<th>In € m</th>
<th>FY 2019</th>
<th>Guidance FY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue and other income</td>
<td>8.0</td>
<td>8.0 to 10.0</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>18.1</td>
<td>20.0 to 24.0</td>
</tr>
<tr>
<td>Operating result (EBIT)</td>
<td>-10.1</td>
<td>-11.0 to -15.0</td>
</tr>
<tr>
<td>Funds required</td>
<td>9.6*</td>
<td>11.0 to 15.0</td>
</tr>
<tr>
<td>Funds required per month</td>
<td>0.8*</td>
<td>0.9 to 1.3</td>
</tr>
</tbody>
</table>

* Excluding capital increases and loan

- Cash reach until mid 2021 based on the current development plan and financial planning
Investment Summary

Developing new options to address major challenges in cancer therapy

• **Disruptive first-in-humans** mode of action provides **high efficacy** and **potential for unique clinical advantages**, including treatment of dormant tumor cells

• **Increased efficacy against 17p deleted and aggressive** tumor cells

• Validated by **high quality collaborations** (early validation and cash)

• Lead product candidate **HDP-101** to enter the clinic

• **High value potential** with proprietary portfolio
## Upcoming conferences and events

<table>
<thead>
<tr>
<th>Upcoming conferences &amp; events</th>
<th>Venue</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIO-Europe Spring – delivered digitally</td>
<td>Virtual</td>
<td>23 – 27 March 2020</td>
</tr>
<tr>
<td>PEGS: The Essential Protein Engineering &amp; Cell Therapy Summit</td>
<td>Boston</td>
<td>4 – 8 May 2020</td>
</tr>
<tr>
<td>Bio€quity Europe (postponed)</td>
<td>Dublin</td>
<td>n/a</td>
</tr>
<tr>
<td>German Spring Conference</td>
<td>Frankfurt</td>
<td>18 – 20 May 2020</td>
</tr>
<tr>
<td>ASCO Annual Meeting</td>
<td>Chicago</td>
<td>29 May – 2 June 2020</td>
</tr>
<tr>
<td>International HealthTech Innovation Days</td>
<td>Paris</td>
<td>22 – 23 June 2020</td>
</tr>
<tr>
<td>World ADC Asia</td>
<td>Tokyo</td>
<td>23 – 25 June 2020</td>
</tr>
</tbody>
</table>

## Financial Calendar

<table>
<thead>
<tr>
<th>Financial Calendar</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1 – Interim Results</td>
<td>April 23, 2020</td>
</tr>
<tr>
<td>Half-year Financial Results</td>
<td>July 09, 2020</td>
</tr>
<tr>
<td>Annual General Meeting (postponed)</td>
<td>July 22, 2020</td>
</tr>
<tr>
<td>Q3 – Interim Results</td>
<td>October 08, 2020</td>
</tr>
</tbody>
</table>
Contact Us

Heidelberg Pharma AG
Schriesheimer Strasse 101
68526 Ladenburg, Germany
Tel.: +49 6203 1009-0
Fax: +49 6203 1009-19
Website: www.heidelberg-pharma.com

IR/PR support
MC Services AG
Katja Arnold (CIRO)
Tel.: +49 89 210 288-40
Email: katja.arnold[at]mc-services.eu

Ticker data
ISIN: DE000A11QVV0
Symbol: WL6
Reuters: WL6G.DE
Bloomberg: WL6.GR